Antegrade Dissection and Re-entry Versus Retrograde Strategy in CTO PCI
Launched by NATIONAL INSTITUTE OF CARDIOLOGY, WARSAW, POLAND · Mar 10, 2025
Trial Information
Current as of April 22, 2025
Not yet recruiting
Keywords
ClinConnect Summary
The ADRENALINE trial is planned as a multicenter, prospective randomized research experiment in patients with clinical indication for PCI of CTO. The target population will comprise patients with at least difficult CTO (J-CTO score ≥2) and angiographic equipoise for either ADR or the retrograde CTO recanalization strategy as evaluated by 2 independent CTO PCI operators. The pre-procedural assessment will comprise cardiac magnetic resonance (CMR) for late gadolinium enhancement, laboratory testing (cardiac troponin, creatine kinase-MB) and health status assessed by the Seattle angina questio...
Gender
ALL
Eligibility criteria
- Inclusion Criteria:
- • clinical indication for CTO PCI as determined by the local heart team (presence of angina or equivalent symptoms and/or documented ischemia or viability)
- • at least difficult native CTO lesion with J-CTO difficulty score ≥2 points on invasive angiography
- • angiographic suitability for both ADR and the retrograde strategy as assessed by 2 independent hybrid CTO PCI operators
- • informed consent for participation in the study
- Exclusion Criteria:
- • \<18 years of age
- • acute myocardial infarction
- • cardiogenic shock
- • severe valvular disease
- • estimated life expectancy \<1 year
- • contraindication to PCI
- • contrast allergy
- • positive pregnancy test or breast-feeding
- • native CTO lesion with easy or intermediate difficulty score on invasive angiography (J-CTO score \<2 points)
- • lack of angiographic equipoise between the ADR and the retrograde strategy as assessed by 2 independent hybrid CTO PCI operators
Trial Officials
Maksymilian Opolski
Principal Investigator
National Institute of Cardiology
About National Institute Of Cardiology, Warsaw, Poland
The National Institute of Cardiology in Warsaw, Poland, is a leading research institution dedicated to advancing the understanding and treatment of cardiovascular diseases. Renowned for its commitment to innovative clinical research, the Institute focuses on improving patient outcomes through comprehensive studies that encompass prevention, diagnosis, and therapeutic strategies. With a multidisciplinary team of experts and state-of-the-art facilities, the National Institute of Cardiology plays a pivotal role in contributing to global cardiovascular knowledge and enhancing clinical practices in the field.
Contacts
Jennifer Cobb
Immunology at National Institute of Allergy and Infectious Diseases (NIAID)
Locations
Warsaw, , Poland
Patients applied
Timeline
First submit
Trial launched
Trial updated
Estimated completion
Not reported